Extract from THE BULL MARKET DRUG AND BIOTECH INVESTOR
for Wednesday, February 23, 2000
---------------------
"With regards to a smaller company, we return to Biomira (BIOM, $12, unch),
as we so often do. They have, in recent weeks announced a further
acquirement of $100 million in funding and have presented positive news
regarding their clinical trials which are currently in progress. The
further investment tells us those who are privy to the day-to-day results
of the clinical trials are confident enough to invest significant
additional cash. That certainly shows confidence that their cancer
vaccines, including Theratope, have a great chance of going to market.
Does this make them a sure bet? No. But what does appear to be true is
that the risk inherent to investing in Biomira is dropping, while the
price is remaining reasonable. This to us is a sure sign to buy. We have
a solid portfolio of secure biotechnology companies, so we can confidently
invest in a more speculative company such as Biomira. This is where we
are shooting for the big winner, and so far, so good." |
